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Persistence of Anti-Desmoglein 3 IgGþ B-Cell Clones
in Pemphigus Patients over Years
Christoph M. Hammers1, Jing Chen1, Chenyan Lin1, Stephen Kacir2, Don L. Siegel2, Aimee S. Payne1 and
John R. Stanley1
Pemphigus vulgaris (PV) is a prototypic tissue-specific autoantibody-mediated disease, in which anti-desmoglein
3 (Dsg3) IgG autoantibodies cause life-threatening blistering. We characterized the autoimmune B-cell response
over 14 patient years in two patients with active and relapsing disease, then in one of these patients after long-
term remission induced by multiple courses of rituximab (anti-CD20 antibody). Characterization of the anti-Dsg3
IgGþ repertoire by antibody phage display (APD) and PCR indicated that six clonal lines persisted in patient 1
(PV3) over 5.5 years, with only one new clone detected. Six clonal lines persisted in patient 2 (PV1) for 4 years, of
which five persisted for another 4.5 years without any new clones detected. However, after long-term clinical and
serologic remission, B11 years after initial characterization, we could no longer detect any anti-Dsg3 clones in
PV1 by APD. Similarly, in another PV patient, B4.5 years after a course of rituximab that induced long-term
remission, anti-Dsg3 B-cell clones were undetectable. These data suggest that in PV a given set of non-tolerant
B-cell lineages causes autoimmune diseases and that new sets do not frequently or continually escape tolerance.
Therapy such as rituximab, aimed at eliminating these aberrant sets of lineages, may be effective for disease
because new ones are unlikely to develop.
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INTRODUCTION
In pemphigus vulgaris (PV), anti-desmoglein 3 (Dsg3)
IgG autoantibodies cause loss of keratinoctye adhesion,
resulting in severe blistering (Amagai et al., 1994; Mascaro
et al., 1997; Mahoney et al., 1999; Payne et al., 2004, 2005).
Conventional therapy consists of corticosteroids and
other immunosuppressives (e.g., mycophenolate mofetil)
(Kasperkiewicz et al., 2012; Hammers et al., 2013).
Recently, the use of rituximab to deplete CD20þ B cells has
been shown to be effective in achieving clinical and
serological remission (Ahmed et al., 2006; Joly et al., 2007;
Lunardon et al., 2012; Leshem et al., 2013). However,
with both therapies, many patients who achieve clinical
remission subsequently relapse (Almugairen et al., 2013).
In this study, we asked why patients relapse. Specifically, is
there an ongoing escape of new IgGþ anti-Dsg3 B-cell
clones from tolerance or do the same B-cell clones persist
over time? The first possibility suggests a basic defect in
tolerance to Dsg3 that allows new lineages of IgGþ anti-Dsg3
B-cell clones to continually develop over time in these
patients, whereas the second suggests that a time-limited
event caused a set of IgGþ anti-Dsg3 B-cell clones to
escape tolerance, and if these could be eliminated disease
might be cured.
We used antibody phage display (APD) to characterize
IgGþ B-cell clones to address this question. APD is a very
sensitive screening method for finding antigen-specific Igs
because it has the capacity for screening up to 108 indepen-
dent monoclonal antibodies in large phage libraries that are
selected by multiple rounds of binding to an antigen, followed
by amplification (Barbas, 2001; Hammers and Stanley, 2014).
Previous studies have shown that APD can be used to detect
anti-Dsg antibodies in both PV and pemphigus foliaceus, and
that the specificity of these autoantibodies is mostly carried by
the IgG heavy chain (Payne et al., 2005; Ishii et al., 2008;
Yamagami et al., 2009, 2010). By sequencing the variable
heavy-chain repertoire, the clonal relatedness of heavy chains
(and the B cells from which they are derived) can be
determined by shared complementarity-determining region 3
(CDR3) nucleotide (or their deduced amino acid) sequences
(Yamagami et al., 2010).
RESULTS
Patient characteristics
Details of the patients, given in Supplementary Table S1
online, are summarized below.
Patient PV3 was first seen in 2006 and treated over 5.5 years
with prednisone and mycophenolate mofetil. He went into
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complete clinical remission off therapy twice (i.e., absence of
new or established lesions with the patient off any systemic
therapy for at least 2 months; see Murrell et al. (2008)), but
disease recurred each time. His B-cell response (some
sequences reported previously by Yamagami et al. (2010))
was analyzed in 2006 (initial analysis, designated PV3) and
B5.5 years later (analysis designated PV3a; Figure 1a). The
second patient’s B-cell response was characterized at initial
presentation in 2002 (designated PV1; sequences previously
reported by Payne et al. (2005)), and then again 4 years later
after routine therapy (PV1a). Additional studies were performed
after three courses of rituximab (each 2 g over 2 weeks), during
which time his anti-Dsg3 IgG serum titer was indeterminate,
and shortly after which disease recurred (PV1b), and then after
a 22-month clinical and serologic remission following a fourth
course of rituximab (PV1c; B11 years after first studied)
(Figure 1b). Both of these patients had mucocutaneous PV
with all relapses involving cutaneous lesions. Such patients
usually have anti-Dsg1 IgG in addition to anti-Dsg3 (Ishii et al.,
1997; Shirakata et al., 1998; Mahoney et al., 1999). Although
we did not check anti-Dsg1 at all time points, patient PV3 had
a Dsg1 ELISA index value of 147 on final relapse (black box
Figure 1), and PV1 had Dsg1 ELISA index values of 96 when
first seen (PV1 red box Figure 1) and of 0.85 at the last time
point studied (PV1c red box Figure 1).
A third PV patient, designated COL-JA, was in clinical and
serological remission off therapy for 56 months (anti-Dsg3/1
serum IgG titers negative) after a single course of rituximab
(4 375 mg m2, over 1 month) when we analyzed her anti-
Dsg3 B-cell response.
Analysis of IgGþ anti-Dsg3 B-cell clones over time in patients
PV3 and PV1 with active and remitting disease
We constructed APD libraries from messenger RNA from
blood mononuclear cells by cloning a PCR-amplified reper-
toire of IgG-variable heavy (VH) and light chains (VL) into the
M13-based phagemid vector pComb3X that allows expression
of a single-chain variable fragment antibody on the surface of
an individual phage (which contains the corresponding
complementary DNA inside) (Barbas, 2001). Multiple rounds
of panning on immobilized Dsg3 allow for increasing enrich-
ment of phage that express anti-Dsg3 antibodies from the
library, if they are present, with each round. We monitored
enrichment of the APD libraries by using a Dsg3-ELISA
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Figure 1. Antibody phage display (APD) libraries: timeline of construction and panning against desmoglein 3 (Dsg3). (a, b) Serum anti-Dsg3 ELISA index values
are indicated by boxes. Above the horizontal dotted line are positive values. Red boxes indicate blood used for APD library construction. Periods of complete
clinical remission off therapy (CROT) are shaded in turquoise. (c) Enrichment for Dsg3-binding was measured by phage ELISA of the libraries amplified after
sequential pannings (further explained in Materials and Methods). Shown is the ratio of the optical density (OD) value from rounds P2–P4 relative to the OD of the
unpanned P0 library (with a value of 1), expressed as arbitrary units (a.u.).
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developed with anti-M13 antibodies (Figure 1c). Patients with
active, recurrent, or impending disease (PV3/3a; PV1/1a/1b)
showed enrichment with multiple pannings. To further char-
acterize the autoimmune B-cell response, we cloned and
genetically analyzed monoclonal anti-Dsg3 antibodies from
phage that enriched on panning (Figure 2; Table 1). Individual
anti-Dsg3 clonal lineages were identified by their shared
VH-CDR3 signatures formed during somatic VDJ-recombina-
tion in pre-B cells. By APD in patient PV3, we detected three
anti-Dsg3 clonal lines (I–III; Figure 2a). In the same patient, we
detected two of these original lines (I and II) and four new
lines (IV–VII) 5.5 years later. Because we routinely sample a
limited number of clones from each round of panning, it is
conceivable that clones are present but not detected by APD.
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Figure 2. Desmoglein 3-specific IgGþ B-cell clonal lineages in two pemphigus patients. For patients (a) PV3 and (b) PV1 each clonal lineage is indicated by
a circle and Roman numeral, grouped in gray-shaded vertical rectangles by time. Clones identified by PCR are outlined in black; others were determined by antibody
phage display (APD). VH/VL-genes used for the VH/VL-chains are shown to the left of each clone. For each clone isolated by APD, VH-chains varying by
somatic mutations (SMs) are indicated to the right of the circle (with the Arabic number corresponding to the Roman numeral of each clone and small letters indicating
distinct SM patterns; e.g., 2a/2b indicates VH-chains with the same VH-CDR3, differing by SM throughout the rest of the VH-chain). The number of actual mutations
(excluding VH-CDR3- and IgG heavy-chain framework 4-regions) compared with germline is indicated in parenthesis. ND: not detected by APD or PCR.
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Therefore, we used PCR with VH-CDR1- or 2- and 3-specific
primers to determine whether clones not detected by APD at
one time point (but that were detected at another time by
APD) in both our PV3 and PV3a libraries were actually present
(Figure 3). We verified the PCR amplification by nucleotide
sequencing of all amplicons. By combining APD and PCR we
could detect all anti-Dsg3 clonal lines at both time points,
except for clone IV, which we found only in relapse
(Figure 2a). We conclude that non-tolerant clonal anti-Dsg3
B-cell lineages persisted in this PV patient over years with only
one possibly new clone forming. A similar study in patient
PV1 had analogous findings (Figure 2b). At the times when this
Table 1. Characterization of IgG anti-Dsg3 B-cell lineages in pemphigus patients PV3 and PV1
Pat. B-cell clone (specificity)1 Translation of the VH-CDR3 (no. of aa)
2 IMGT VH gene
3
IMGT VL genes
4
PV3 PV3a
PV3 I (D3) ARDLGGFDFDY
(11)
1-46*03/01 k2-8*01 k2-8*01
k2-14*02
II (D3) ARDQSLGMDV (VH 2a)
ARDESLGMDV (VH 2b)
(10)
1-46*03/01 k2-14*01 k2-8*01
III (D3) ARINYYDGSGHHSDADYM
(18)
5-a*03 k1-51*01 ND
IV (D3) AKGMHDIVVMIGSTYYYYYGLDV
(23)
3-23*01 ND l3-10*01
V (D3) TREGPGYSSGSFHV
(14)
4-59*03 ND j3-11*01
VI (D3) AKGYGDDHDASDI
(13)
3-30*18/03 ND k1-39*01/
j1D-39*01
VII (D3) ARDRGVLFRNFFDL
(14)
1-2*02/04/05 ND j3-15*01
Pat. B-cell clone (specificity)1 Translation of the VH-CDR3 (no. of aa)
2 IMGT VH gene
3
IMGT VL genes
4
PV1 PV1a PV1b
PV15 I (D3) ARDKAAYYESGYYYIGDF (7/9 VH)
ARDKEAYYESGYYYIGDF (VH 1e)
ARDKAAYYEAGYYYIGDF (VH 1h)
(18)
1-69*06 k1-44*01
k1-47*01/02
k1-44*01
k1-47*02
k1-47*02
II (D3) ASGGVVDFDH
(10)
3-7*01 l2-23*01/03 ND ND
III (D3) VRDGSEFLNLPSGHDVFDI (8/9 VH)
VRDGSEFLNLPSGHDAFDI (VH 3b)
(19)
1-18*04 ND j4-1*01 j4-1*01
IV (D3) AREALVYYDSSGYYKGGFDY
(20)
3-30*04 j3-11*01/02 ND ND
V (D31) ARGWHRTGFRGYPSHWYFDL
(20)
4-4*02 k1-47*02 k1-47*02 k1-47*02
VI (D31) ARGGDYSGWYNFDY
(14)
1-69*09 l3-9*01
l3-1*01
l3-9*01 ND
Abbreviations: APD, antibody phage display; CDR3, complementarity-determining region 3; Dsg3, Desmoglein 3; IMGT, international ImMunoGeneTics
information system; ND, not determined; Pat., patient; PV, pemphigus vulgaris.
1We obtained clones specific for Dsg3 (D3) and for both Dsg3 and Dsg1 (D31) by panning APD libraries on Dsg3.
2B-cell lineages were defined by shared VH-CDR3-deduced amino-acid (aa) sequences (allowing one aa change, presumably due to somatic mutation; blue).
3Gene usage was determined by matching VH/VL-nucleotide sequences to the IMGT database. Note that VH/VL-gene usage, as detected by APD, in anti-Dsg3
antibodies is not completely random but in many cases, for the same clonal VH chain the VL gene for the paired VL-chain is the same over time (see PV3-PV3a
clone I, PV1-PV1a-PV1b clone I, PV1a-PV1b clone III, PV1-PV1a-PV1b clone V, PV1-PV1a clone VI). This shows that although VH/VL-pairing in cloning the
APD library is theoretically random, only very specific light chains can pair with the VH-chains in making anti-Dsg3 antibodies. Bold typeface of VH/VL-genes
indicates that these genes were found in pemphigus anti-Dsg3 antibodies by EBV-transformed memory B cell or human–mouse heterohybridoma in other
studies (Qian et al., 2007; Di Zenzo et al., 2012). In addition, the VH/VL-gene pairing for PV3a clone VI (underlined) has previously been found by
heterohybridoma cloning of pemphigus antibodies (Qian et al., 2007).
4ND indicates the VL gene not determined because PCR, not APD, was used to detect the VH.
5Library PV1c is not shown as no clones were detected by either APD or PCR.
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patient had active, remitting, and relapsing disease, six anti-
Dsg3 B-cell clonal lines were detected by APD and PCR; all
these clones were present in PV1a 4 years later, and five were
detected another 4.5 years later (PV1b). No new clonal lines
were detectable over these 8.5 years.
IgGþ anti-Dsg3 B-cell clones were not detectable after
long-term clinical and serological remission induced by rituximab
No clones could be detected by either APD or PCRB11 years
after initial analysis, after patient PV1, treated with four
courses of rituximab, maintained a clinical and serological
remission off therapy forB22 months (PV1c). To confirm this
finding, we tested another patient treated with rituximab in
complete clinical and serologic remission off therapy forB56
months (COL-JA). In this patient no anti-Dsg3 clones could be
detected by APD as well. These findings are in marked
contrast to all active pemphigus patients we have tested by
APD so far (3 PV, 2 pemphigus foliaceus), in whom we always
found multiple anti-Dsg clonal lineages (Payne et al., 2005;
Ishii et al., 2008; Yamagami et al., 2009; and unpublished).
These findings indicate that even in some patients who
have the potential to actually develop PV, if rituximab
effectively eliminates the pathogenic clones, they no longer
have detectable IgGþ anti-Dsg3 B cells that are escaping
tolerance. Taken together with the persistence of the same
autoimmune B-cell clones persisting for years in active and
remitting disease, these data suggest that rituximab works, at
least in some patients, by eliminating sets of established
pathogenic clones that are not, or rarely, replaced by new
sets of autoimmune B-cell clones.
Analysis of somatic hypermutation and variable light-chain usage
over time
Analyzing the nucleotide sequences encoding the anti-Dsg3
VH-chains over time allowed us to determine that affinity
maturation was generally not an ongoing process in the
autoimmune response of PV, because in most clones the
number of somatic mutations was stable over time (Figure 2).
Occasionally, we found the exact VH-nucleotide sequence at
different time points (VH 1c, 3a, 5a, 6a in patient PV1; 1a in
PV3; Figure 2). This was not from cross-contamination
between libraries, because we used barcoded PCR primers
to distinguish libraries (see Materials and Methods). These data
also show that B cells producing identical VH-chains can
persist for up to 8.5 years and are not necessarily replaced
by more somatically mutated clones.
Furthermore, we analyzed the light-chain usage of the
anti-Dsg3 clones found by APD (Table 1). Although when
constructing libraries by APD, heavy- and light-chain pairing
is theoretically random, these data show that with libraries
made at different time points, for the same preserved heavy-
chain clones, certain light-chain families are definitely favored
for pairing.
DISCUSSION
The basic findings of this study are that clonal lineages of
IgGþ anti-Dsg3 B cells can persist up to 8.5 years even after
rituximab therapy; that patients with recurrent disease main-
tain the same set of persistent B-cell clonal lineages over many
years and even maintain the same exact B-cell clone (i.e., with
the same somatic mutations throughout the entire VH––e.g.,
Std nC1 nC2 pC1 pC2 T (PV3a)
PV3
Clone III
Expected
Retrieved
Expected
Retrieved T1
Retrieved T2
PV1
Clone II
Std nC1 nC2 pC1 pC2 T1 (PV1a) T2 (PV1b)
CDR1 CDR2 CDR3 CDR1 CDR2 CDR3
V J V D J
Linker F1 F2 RVL VHompseqSfi I dpseq
HA tag
6H tag
Sfi I
GNIDPFDGYTNYGPSFQGHVNISNDKALNSVYLQWRSLKTSDAMYFCARINYYDGSGHHSDADYMW
GNIDPFDGYTNYGPSFQGHVNISNDKALNTVYVQWSSLRTSDAMYYCARINYYDGSGHHSDADYMW
ANINQDGNEKHYVDSVKGRFIISRDNTQNSLFLQMNSLRAEDAAVYYCASGGVVDFDHWG
ANINQDGNEKHYVDSVKGRFIISRDNTQNSLFLQMNSLRAEDAAVYYCASGGVVDFDHWG
ANINQDGNEKHYADSVKGRFIISRDNTQNSLFLQMNSLRAEDAAVYYCASGGVVDFDHWG
Figure 3. PCR strategy to identify patient-specific VH-complementarity-determining regions 3 (CDR3s) found by antibody phage display (APD) at one time
point but not at another. (a) PCR template with forward primer from either CDR1 or CDR2 (F1, F2) and reverse primer from CDR3 (R). (b) PV3 clone III, isolated
by APD in 2006, was not found by APD in PV3a (2012), but was identified by PCR (lane T(PV3a)). (c) PV1 clone II was found by APD in 2002, but only by
PCR at later times (lanes T1(PV1a) and T2(PV1b)). Deduced amino-acid (aa) sequences from sequencing of PCR products shown below the gels (retrieved),
compared with that of the corresponding APD-isolated clone (expected). Presumed somatic mutations (or PCR errors) are in red, VH-CDR2/3 regions in bold
font, and primer-covered regions are underlined. Std, 200 bp standard; nC1, negative control (water); nC2, negative control (VH-complementary DNA from
an unrelated PV patient); pC1, positive control (monoclonal phagemid DNA of clone); pC2, positive control (polyclonal plasmid DNA from the APD library from
which the clone of interest was identified by panning).
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PV3 I-1a, PV1 I-1c, III-3a, V-5a, VI-6a in Figure 2); and that in
PV patients new lines of IgGþ anti-Dsg3 B-cell clones do not
continuously escape from tolerance, giving rise to new sets
forming over time. There may have been one exception (clone
IV in PV3a); however, we cannot rule out that this was a minor
clone in PV3 that we could not detect or that the cells that
produced this antibody were not circulating at the time blood
mononuclear cells were obtained for APD-library cloning. The
data for all the other clones and time points suggest that there
is no basic defect in maintaining IgGþ B-cell tolerance to
Dsg3 in PV patients that would allow new sets of anti-Dsg3
B-cell clonal lines to escape over time. In contrast, in systemic
lupus erythematosus and multiple sclerosis, there is ongoing
escape from peripheral tolerance at the mature naive B-cell
level (Yurasov et al., 2006; Kinnunen et al., 2013), which
eventually may mature to IgG-mediated autoimmunity.
Further evidence to support that there is no ongoing defect
permitting escape from tolerance of new IgGþ B-cell clones
in PV is that elimination of all persistent clones detected prior
to ablation by rituximab is associated with long-term serologic
and clinical remission off therapy, which was also previously
demonstrated by flow cytometry of IgGþ anti-Dsg3 B cells
(Colliou et al., 2013). Our study confirms that finding by
looking at the loss of the specific persistent anti-Dsg3 B-cell
lines (identified by their VH-CDR3 sequences) with APD, a
very sensitive technique for cloning rare antibody subsets
(Barbas, 2001; Hammers and Stanley, 2014). Although some
of the original APD-cloned sequences of PV3 and PV1 at the
first time point (PV3 and PV1 red boxes in Figure 1) were
reported previously (Payne et al., 2005; Yamagami et al.,
2010), what is unique about this study is the characterization
of the APD-derived clones over time.
Of course with any technique analyzing autoreactive B
cells, some may have been missed, but we have no reason to
believe that the clones we found here are in any way not
representative of the autoantibody B-cell clone repertoire as a
whole. It is clear that the antigen-specific clonal lines we find
are preserved over years. There is no reason to think we would
find only clones that are preserved but not those that are not
by these methods. In other words, we think it is very unlikely
that somehow APD would only miss finding newly emergent
clones not present at previous time points. Finally, to study
clones over time, APD is probably the most sensitive tech-
nique for picking up minor or rare clones because of the large
number of antibody-bearing phage clones that can be
screened.
The basic idea that elimination of autoreactive B cells and
regeneration of the B-cell repertoire from pro-B-cell precursors
can re-establish tolerance, has been suggested by previous
studies. This conclusion has mostly been through studies of
clonal expansions of B cells in disease, with elimination of
those expansions in remission. For example, in anti-myelin-
associated glycoprotein neuropathy, in which IgM-antibodies
mediate disease activity, response to CD20-ablative therapy,
compared with nonresponders, is associated with better
elimination of clonally expanded IgMþ B cells (Maurer
et al., 2012). Similarly, in three PV patients, assessment of
VH-CDR3 length distributions (i.e., immunoscope analyses)
indicated clonal expansions, and only the patient in complete
remission showed normalization, suggesting elimination of
aberrant, presumably pathologic, B-cell clones (Mouquet
et al., 2008; Colliou et al., 2013). These studies suggested
that elimination of B-cell clones in Dsg-autoantibody-
mediated diseases is associated with remission but did not
specifically trace ablation over time to study whether the same
clones recur or, in fact, whether these or new clonal
expansions arise in recurrence.
The finding that we cannot identify APD clones that bind
Dsg3 in the two PV patients in long-term remission (PV1c and
COL-JA) (Figure 1) and in other individuals without pemphigus
(Yamagami et al., 2009, and unpublished), indicates that
random VH/VL-pairing does not result in artifactual Dsg3-
binding autoantibodies and may suggest that light-chain
receptor editing (Luning Prak et al., 2011) is not the basic
mechanism by which humans maintain tolerance to the
peripheral B-cell antigen Dsg3. Receptor editing would
mean that during B-cell ontogeny, if a heavy–light-chain
pairing causes anti-Dsg reactivity, the light chain is ‘edited
out’ in that autoimmune B cell, and another light chain is
used in its place that does not result in an autoantibody. This
tolerance mechanism would result in normals (with B-cell
tolerance to Dsg) having potentially pathogenic heavy chains
in their repertoire that just need the correct light-chain pairing
to form a pathogenic anti-Dsg antibody. However, in APD we
allow any light chain to recombine with any heavy chain
(Marzari et al., 2001; Qian et al., 2007), and we do not find
anti-Dsg autoantibody formation. Although it is possible that
there is no possible light chain in the entire B-cell repertoire to
pair with a potentially pathogenic heavy chain to reform an
anti-Dsg antibody, it is unlikely as we also show here, and
have shown previously (Payne et al., 2005; Ishii et al.,
2008; Yamagami et al., 2009), that several different light
chains in pemphigus patients with clinically overt disease are
capable of pairing to form such a Dsg3 antibody. However,
further study would be necessary to rigorously validate this
suggestion.
Although we have only been able to study three PV patients,
we feel the findings are relevant to understanding PV and its
therapy. First of all, these are human immunological studies.
The importance of studying human immunology has recently
been highlighted (Anonymous, 2013; Mestas and Hughes,
2004; Davis, 2008). Second, much of our insight into sponta-
neous autoimmune diseases is from inbred so-called auto-
immune mouse strains (e.g., NOD mice for diabetes, NZB
mice for systemic lupus erythematosus). In the same way,
individual humans, although of one genotype (like inbred
mice with one genotype), allow insights into the immunology
of spontaneously occurring human autoimmunity. Third, the
major finding that in patients with PV new B-cell clonal lines
rarely newly escape from tolerance was validated in two
patients over several time points representing 14 patient years,
and in a third patient in long-term remission. However, with
the small number of patients studied, we cannot conclude that
our findings would hold for all pemphigus patients.
Although rituximab clearly eliminates IgGþ anti-Dsg3
B-cell clones, it may have additional effects on maintaining
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tolerance through expansion of regulatory CD38high B cells
(Bregs) that may downregulate Dsg3-specific CD4þ T-helper
cells, which are also decreased after rituximab (Eming et al.,
2008; Colliou et al., 2013). However, CD4þ T-helper cells
may also be decreased because of a lack of Dsg3-specific B
cells to present the autoantigen and activate them (Eming
et al., 2008).
In summary, our findings show that the same clonal IgGþ
anti-Dsg3 B-cell lines persist over 14 patient years in patients
with active disease, even after complete clinical remission off
therapy, but in two patients in long-term clinical and sero-
logical remission no IgGþ B-cell clones were detectable in
the blood (11 and 15 years after active disease). It is possible
that some clones are hidden (e.g., in the bone marrow; Hamza
et al. (2012)) and that these may ultimately reappear to cause
relapse. If, indeed, these patients ultimately recur then we
expect that the same clonal lines would be detected; however,
so far, no recurrence has been seen. The implication of our
findings is that for effective therapy, in at least some patients,
and for potential cure of PV, we should seek therapies adept at
eliminating all existing anti-Dsg3 B-cell clones, e.g., higher
doses or varying dose schedules of rituximab and/or treating
early disease (Lunardon et al., 2012; Colliou et al., 2013), at
which time it may be easier to fully eliminate such clones, and
new ones are unlikely to escape tolerance.
MATERIALS AND METHODS
Further information is available in Supplementary Data online.
Patients and clinical definitions
The study was conducted according to the Declaration of Helsinki
Principles. Written informed consent, approved by the Institutional
Review Board of the University of Pennsylvania, was obtained from
patients PV3 and PV1. From those two patients with a confirmed
diagnosis of PV (see Supplementary Methods online for details)
B50 ml blood was obtained to isolate peripheral blood mononuclear
cells. Clinical data, peripheral blood mononuclear cells, and
serum from patient COL-JA were obtained from Pascal Joly, Rouen,
France.
Anti-Dsg3/1 serum ELISA
Titers of IgG antibodies against Dsg3/1 were determined with the
Mesacup Dsg3/1 ELISA kits (MBL, Woburn, MA), following the
manufacturer’s instructions.
APD-library construction and selection of anti-Dsg3-expressing
phage clones
Detailed methods for constructing an APD library have been
previously published (Barbas, 2001; Payne et al., 2005). Peripheral
blood mononuclear cell-RNA was extracted using the RNeasy Midi
Kit (Qiagen, Valencia, CA). Complementary DNA was generated
from RNA with a SuperScript First-Strand Synthesis System for RT-PCR
(Invitrogen, Carlsbad, CA). We separately constructed IgGk/IgGl
APD libraries using the phagemid vector pComb3X (Scripps
Research Institute, La Jolla, CA). During PCR amplification of IgG
VH-transcripts from complementary DNA, the standard HSCG1234-B
reverse primer was barcoded at the SpeI-site to distinguish phage
clones derived from each APD library in one patient (PV3:
HSCG1234-B; PV3a: HSCG1234-E; PV1: HSCG1234-B; PV1a:
HSCG1234-C; PV1b: HSCG1234-D; PV1c: HSCG1234-G; COL-JA:
HSCG1234-H; see Supplementary Table S2 online). Care was taken
to prevent cross-contamination between libraries (see Supplementary
Methods online). Phagemid libraries of at least 108 independent
transformants were electroporated into XL-1 Blue E.coli (Agilent,
Santa Clara, CA), and the recombinant phage was purified, after
addition of VCSM13 helper phage (Agilent), from culture supernatants
using polyethylene glycol precipitation. The diversity of each
unpanned library was determined by random sampling of B20
phage clones, phagemid extraction with a plasmid preparation system
(Qiagen), and Sanger sequencing for VH/VL-gene usage and VH/L-
CDR3 sequences (obtained sequences were subjected to an online
database search at IMGT/V-QUEST and vbase2, accessible at http://
www.imgt.org and http://www.vbase2.org). Equal numbers of
unpanned P0-IgGk and P0-IgGl transformants were combined to
select for Dsg3-binders during four rounds of ag-guided selection
(panning) on immobilized Dsg3 substrate (MBL). Resulting polyclonal
phage pools were diluted to 1:1,000 and 1:5,000 and tested for
specificity toward Dsg3 by ELISA using HRP-conjugated anti-M13
antibody (1:5,000; GE Healthcare, Pittsburgh, PA) for developing on
Dsg3 substrate. If these pools of phage bind Dsg3, the peroxidase-
conjugated anti-phage antibody renders a change in color, indicating
enrichment of antigen-specific phage; for comparison, we calculated
the ratio of the optical densityvalue from panning rounds P2–P4
relative to the optical density of the unpanned (P0) phage library
(which was set¼ 1; ratio expressed as arbitrary units, a.u.). In case
of Dsg3-specific enrichment of phage pools, individual phage
monoclonals were isolated from those panning rounds with
positive readings (usually rounds 2–4; B40 for each panned library).
Obtained phagemids were analyzed for shared VH-CDR3 signatures,
VH/VL-gene usage, and somatic mutations (IMGT, vbase2). In
addition, all individual monoclonals were retested on Dsg3 substrate
for binding, using the anti-M13 ELISA detailed above.
Clone-specific PCR
To determine whether B-cell clones identified at time point 1 by APD
were present at time point 2 in the same patient (if they could
not be found at that latter time point by APD), we obtained poly-
clonal pComb3X-scFv phagemid DNA as PCR template from the
unpanned (P0) or once panned (P1) library made at time point 2. The
VH-coding segments in the inserts were further PCR-amplified using
ompseq and dpseq sequencing primers annealing up- and down-
stream to the insert (Figure 3; primers at 20mM; 50 94 1C, then 30
cycles of 150 0 94 1C, 150 0 66 1C, 900 0 72 1C, then 100 72 1C). In some
cases, gel-purified VH-DNA (used for construction of the APD library
at time point 2) was used instead of the latter PCR product. On these
templates, a second PCR with primers specific for the VH-CDR2/3
regions (all primers were obtained from Sigma-Aldrich, St Louis, MO)
was performed (alternatively, primers were designed to anneal to the
VH-CDR1 and VH-CDR3 regions). The sequences of these primers
were determined from the clones isolated by APD from time point 1
and are given in Supplementary Table S2 online. All nested PCR
products were gel-purified (Qiagen), TOPO-TA cloned (Invitrogen),
and Sanger sequenced.
ORCIDs
Christoph M Hammers: http://orcid.org/0000-0001-5631-2415
CM Hammers et al.
Persistence of Anti-Dsg3 IgGþ B-Cell Clones
748 Journal of Investigative Dermatology (2015), Volume 135
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This research was supported by a research fellowship from the DFG (HA6736/
1-1) to CMH and by grants R01-AR052672 and P30-AR057217 from the
NIAMS and NIH to JRS. We thank Pascal Joly, Department of Dermatology,
Inserm U905, Institute for Research and Innovation in Biomedicine, Rouen
University Hospital, University of Normandy, F-76031 Rouen, France, for
providing us with clinical data, peripheral blood mononuclear cells, and serum
from patient COL-JA, and Eline T Luning Prak for reviewing the manuscript.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Anonymous (2013) Of men, not mice. Nat Med 19:379
Ahmed AR, Spigelman Z, Cavacini LA et al. (2006) Treatment of pemphigus
vulgaris with rituximab and intravenous immune globulin. N Engl J Med
355:1772–9
Almugairen N, Hospital V, Bedane C et al. (2013) Assessment of the rate of
long-term complete remission off therapy in patients with pemphigus
treated with different regimens including medium- and high-dose cortico-
steroids. J Am Acad Dermatol 69:583–8
Amagai M, Hashimoto T, Shimizu N et al. (1994) Absorption of pathogenic
autoantibodies by the extracellular domain of pemphigus vulgaris antigen
(Dsg3) produced by baculovirus. J Clin Invest 94:59–67
Barbas CF III (2001) Phage Display: A Laboratory Manual. Cold Spring Harbor
Laboratory Press: Cold Spring Harbor, NY, USA
Colliou N, Picard D, Caillot F et al. (2013) Long-term remissions of severe
pemphigus after rituximab therapy are associated with prolonged failure
of desmoglein B cell response. Sci Transl Med 5:175ra30
Davis MM (2008) A prescription for human immunology. Immunity 29:835–8
Di Zenzo G, Di Lullo G, Corti D et al. (2012) Pemphigus autoantibodies
generated through somatic mutations target the desmoglein-3 cis-inter-
face. J Clin Invest 122:3781–90
Eming R, Nagel A, Wolff-Franke S et al. (2008) Rituximab exerts a dual effect in
pemphigus vulgaris. J Invest Dermatol 128:2850–8
Hammers CM, Lunardon L, Schmidt E et al. (2013) Contemporary management
of pemphigus. Expert Opin Orphan Drugs 1:295–314
Hammers CM, Stanley JR (2014) Antibody phage display: technique and
applications. J Invest Dermatol 134:e17
Hamza N, Bootsma H, Yuvaraj S et al. (2012) Persistence of immunoglobulin-
producing cells in parotid salivary glands of patients with primary Sjogren’s
syndrome after B cell depletion therapy. Ann Rheum Dis 71:1881–7
Ishii K, Amagai M, Hall RP et al. (1997) Characterization of autoantibodies in
pemphigus using antigen-specific enzyme-linked immunosorbent assays
with baculovirus-expressed recombinant desmogleins. J Immunol
159:2010–7
Ishii K, Lin C, Siegel DL et al. (2008) Isolation of pathogenic monoclonal anti-
desmoglein 1 human antibodies by phage display of pemphigus foliaceus
autoantibodies. J Invest Dermatol 128:939–48
Joly P, Mouquet H, Roujeau JC et al. (2007) A single cycle of rituximab for the
treatment of severe pemphigus. N Engl J Med 357:545–52
Kasperkiewicz M, Schmidt E, Zillikens D (2012) Current therapy of the
pemphigus group. Clin Dermatol 30:84–94
Kinnunen T, Chamberlain N, Morbach H et al. (2013) Specific peripheral
B cell tolerance defects in patients with multiple sclerosis. J Clin Invest
123:2737–41
Leshem YA, Hodak E, David M et al. (2013) Successful treatment of pemphigus
with biweekly 1-g infusions of rituximab: a retrospective study of 47
patients. J Am Acad Dermatol 68:404–11
Lunardon L, Tsai KJ, Propert KJ et al. (2012) Adjuvant rituximab therapy of
pemphigus: a single-center experience with 31 patients. Arch Dermatol
148:1031–6
Luning Prak ET, Monestier M, Eisenberg RA (2011) B cell receptor editing in
tolerance and autoimmunity. Ann N Y Acad Sci 1217:96–121
Mahoney MG, Wang Z, Rothenberger K et al. (1999) Explanations for the
clinical and microscopic localization of lesions in pemphigus foliaceus
and vulgaris. J Clin Invest 103:461–8
Marzari R, Sblattero D, Florian F et al. (2001) Molecular dissection of the tissue
transglutaminase autoantibody response in celiac disease. J Immunol
166:4170–6
Mascaro JM Jr., Espana A, Liu Z et al. (1997) Mechanisms of acantholysis in
pemphigus vulgaris: role of IgG valence. Clin Immunol Immunopathol
85:90–6
Maurer MA, Rakocevic G, Leung CS et al. (2012) Rituximab induces sustained
reduction of pathogenic B cells in patients with peripheral nervous system
autoimmunity. J Clin Invest 122:1393–402
Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse
and human immunology. J Immunol 172:2731–8
Mouquet H, Musette P, Gougeon ML et al. (2008) B-cell depletion immuno-
therapy in pemphigus: effects on cellular and humoral immune responses.
J Invest Dermatol 128:2859–69
Murrell DF, Dick S, Ahmed AR et al. (2008) Consensus statement on definitions
of disease, end points, and therapeutic response for pemphigus. J Am
Acad Dermatol 58:1043–6
Payne AS, Hanakawa Y, Amagai M et al. (2004) Desmosomes and disease:
pemphigus and bullous impetigo. Curr Opin Cell Biol 16:536–43
Payne AS, Ishii K, Kacir S et al. (2005) Genetic and functional characterization
of human pemphigus vulgaris monoclonal autoantibodies isolated by
phage display. J Clin Invest 115:888–99
Qian Y, Diaz LA, Ye J et al. (2007) Dissecting the anti-desmoglein autoreactive
B cell repertoire in pemphigus vulgaris patients. J Immunol 178:5982–90
Shirakata Y, Amagai M, Hanakawa Y et al. (1998) Lack of mucosal involve-
ment in pemphigus foliaceus may be due to low expression of desmoglein
1. J Invest Dermatol 110:76–8
Yamagami J, Kacir S, Ishii K et al. (2009) Antibodies to the desmoglein 1
precursor proprotein but not to the mature cell surface protein cloned
from individuals without pemphigus. J Immunol 183:5615–21
Yamagami J, Payne AS, Kacir S et al. (2010) Homologous regions of auto-
antibody heavy chain complementarity-determining region 3 (H-CDR3)
in patients with pemphigus cause pathogenicity. J Clin Invest 120:
4111–7
Yurasov S, Tiller T, Tsuiji M et al. (2006) Persistent expression of autoantibodies
in SLE patients in remission. J Exp Med 203:2255–61
CM Hammers et al.
Persistence of Anti-Dsg3 IgGþ B-Cell Clones
www.jidonline.org 749
